|1.||Indik, Julia H: 7 articles (07/2015 - 07/2008)|
|2.||Kern, Karl B: 5 articles (07/2015 - 07/2008)|
|3.||McGovern, Meghan: 3 articles (07/2015 - 09/2014)|
|4.||Conover, Zacherie: 3 articles (07/2015 - 09/2014)|
|5.||Allen, Daniel: 3 articles (03/2015 - 12/2009)|
|6.||Neubauer, Andreas: 3 articles (06/2013 - 08/2002)|
|7.||Tang, Wanchun: 3 articles (12/2011 - 04/2002)|
|8.||Weil, Max Harry: 3 articles (12/2011 - 04/2002)|
|9.||Spaite, Daniel W: 2 articles (07/2015 - 09/2014)|
|10.||Silver, Annemarie E: 2 articles (07/2015 - 09/2014)|
|1.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
05/01/1983 - "Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)."
10/01/1986 - "These studies provide quantitative information on the therapeutic index of AMSA and support the inclusion of this drug in first-line treatment regimens for acute myelocytic leukemia."
10/01/1982 - "We conclude that it is possible to given m-AMSA as a continuous infusion and that studies should be undertaken in patients with acute myelogenous leukemias to compare the efficacy of m-AMSA infusion with conventional bolus administration as a means to enhance the duration of response."
10/01/1986 - "The efficacy of AMSA was evaluated quantitatively in a rat model (BNML) relevant for human acute myelocytic leukemia. "
01/01/1984 - "AMSA: a phase II trial in resistant and recurrent acute myelogenous leukemia."
01/01/1986 - "Amsacrine (NSC 249 992) is a new anticancer drug which, although effective for the treatment of various disseminated tumors, has shown disappointing activity against most solid tumors. "
07/01/1981 - "m-AMSA is much less effective against cells within these tumor-like structures than it is against exponential-phase V79-171b cells in monolayer cultures, the initial D0 of the survival curve for the latter being approximately 10-fold lower than for the former following a 60-min exposure to the drug. "
06/01/1988 - "These drugs, including m-AMSA and VP16-23, are proving useful in the treatment of several neoplasms."
07/01/1981 - "The use of sequential trypsinization techniques to recover cells at varying depths within spheroids demonstrates that a 60-min m-AMSA treatment preferentially kills cells nearest the spheroid surface, suggesting that tumor cells at a distance from the vasculature may limit the efficacy of m-AMSA in vivo."
10/01/1997 - "Results of amsacrine studies in different solid tumors with a dose of 85 mg/m2/24 h x 1 quo 3 weeks have been, in general, disappointing. "
02/01/1984 - "Prediction of complete remission in patients with refractory acute leukemia treated with AMSA."
07/01/1980 - "4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia."
09/15/1991 - "Amsacrine is safe and effective therapy for patients with myocardial dysfunction and acute leukemia."
07/01/1985 - "We conclude that amsacrine as a single agent is not a useful treatment for relapsed, heavily pretreated adult and pediatric acute leukemia."
11/01/1983 - "This cooperative group pilot study confirms previous reports from single institutions that amsacrine is a useful drug in the treatment of refractory adult acute leukemia and is worthy of further study."
|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
01/01/1991 - "Effects of amsacrine in combination with other anticancer agents in human acute lymphoblastic leukemia cells in culture."
11/01/1982 - "Treatment of refractory adult lymphoblastic leukemia (ALL) with 4'(9-acridinylamino) methanesulfon-M-anisidide (AMSA)."
08/01/1988 - "Thirty-six patients with relapsed acute lymphoblastic leukemia (ALL) and four with primary refractory ALL were treated with a regimen that included amsacrine, 200 mg/m2, intravenously daily for three days with cytarabine, 3 gm/m2, by infusion over three hours daily for five days. "
08/01/1988 - "Amsacrine with high-dose cytarabine is highly effective therapy for refractory and relapsed acute lymphoblastic leukemia in adults."
12/01/1986 - "High-dose cytosine arabinoside with amsacrine for treatment of acute lymphoblastic leukemia."
10/01/1997 - "High dose amsacrine seems to be a toxic, but very effective drug as first-line treatment for poorly differentiated carcinoma of meso and hypopharynx, and further studies seem warranted."
10/01/1997 - "Thus, in the second step of this study, high dose amsacrine was evaluated in the target group of previously untreated patients with advanced grade III/IV carcinoma of meso and hypopharynx. "
10/01/1997 - "A two-step reevaluation of high-dose amsacrine for advanced carcinoma of the upper aerodigestive tract: a pilot phase II study."
05/01/1985 - "Phase II study of amsacrine in gastric carcinoma: a southwest oncology group study."
11/01/1984 - "Phase II trial of amsacrine in pancreatic carcinoma: a Southwest Oncology Group study."
|4.||Etoposide (VP 16)
|9.||DNA (Deoxyribonucleic Acid)
|1.||Drug Therapy (Chemotherapy)
|2.||Cardiopulmonary Resuscitation (CPR)
|3.||Heterologous Transplantation (Xenotransplantation)
|4.||Hematopoietic Stem Cell Transplantation